The immediate exercise of existing warrants provides near-term cash, but the issuance of new warrants for 2x the exercised shares creates a massive overhang. Watch for the resale registration filing within 15 days, which could enable the investor to sell the new warrant shares and pressure the stock. The stock is likely to face selling pressure from both the registered warrant exercise shares and the eventual resale of new warrant shares.
Price Chart
Executive Summary
Autonomix Medical entered into a warrant inducement agreement with an existing investor, resulting in the immediate cash exercise of 428,731 Series C warrants at a reduced price of $6.00 per share for gross proceeds of approximately $2.6 million. In exchange, the company issued new unregistered Series D-1 and D-2 warrants to purchase up to 857,462 additional shares at $5.75 per share, creating massive potential dilution relative to the company's $3 million market cap.
Key Financial Metrics
Key Facts
- Gross proceeds of approximately $2.6 million from exercise of 428,731 shares at $6.00 per share.
- Company issued new Series D-1 and D-2 warrants to purchase up to 428,731 shares each (total 857,462) at $5.75 per share, exercisable immediately for 5.5 years.
- New warrants are unregistered and issued under Section 4(a)(2) of the Securities Act.
- Company agreed to file a resale registration statement for the new warrant shares within 15 days and use best efforts to have it declared effective within 45-75 days.
- Maxim Group LLC acted as warrant solicitation agent, receiving a 7% cash fee and up to $15,000 in expense reimbursement.
- Closing expected on or about July 15, 2026.
Financial Impact
The company receives approximately $2.6 million in gross proceeds but incurs potential dilution of up to 857,462 additional shares from the new warrants, which is substantial relative to the current $3 million market cap.
Risk Factors
- Massive potential dilution from 857,462 new warrant shares relative to current market cap of $3M.
- Resale registration filing may lead to accelerated selling by the investor.
- Company's reliance on further financing given its early-stage status and cash burn.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-023638 |
| Exhibit: ex_988126.htm | 0001437749-26-023638 |
| Exhibit: ex_988127.htm | 0001437749-26-023638 |
| Exhibit: ex_988128.htm | 0001437749-26-023638 |
| Document: amix20260714c_8k.htm | 0001437749-26-023638 |
| Document: 0001437749-26-023638-index-headers.html | 0001437749-26-023638 |
| Document: 0001437749-26-023638-index.html | 0001437749-26-023638 |
| Document: 0001437749-26-023638.txt | 0001437749-26-023638 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 14d ago | 3 | $3.01 | awaiting T+20 | — | $2.10 (−30.15%) |
Oct 2, 2026 25d ago | Press Release | $3.78 | awaiting T+20 | — | $2.10 (−44.38%) |
Sep 16, 2026 5w ago | 8-K | $4.12 $3.01 | ▼ −26.94% | ▼ −30.12% | $2.10 (−48.97%) |
Sep 16, 2026 5w ago | EFFECT | $4.12 $3.01 | ▲ +26.94% | ▲ +30.12% | $2.10 (+48.97%) |
Sep 11, 2026 6w ago | 424B5 | $4.33 $3.10 | ▲ +28.41% | ▲ +30.67% | $2.10 (+51.44%) |
Sep 4, 2026 7w ago | S-3 | $4.58 $3.47 | ▲ +24.24% | ▲ +25.95% | $2.10 (+54.09%) |
Aug 26, 2026 8w ago | 8-K | $5.63 $4.07 | ▼ −27.71% | ▼ −27.20% | $2.10 (−62.65%) |
Aug 5, 2026 11w ago | EFFECT | $12.10 $4.50 | ▼ −62.81% | ▼ −62.21% | $2.10 (−82.62%) |
Jul 28, 2026 13w ago | 8-K | $2.75 $7.19 | ▲ +161.45% | ▲ +158.07% | $2.10 (−23.54%) |
Jul 15, 2026 14w ago | 8-K | $4.92 $6.86 | ▼ −39.43% | ▼ −35.81% | $2.10 (+57.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers